1996
Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma
Wilson L, Quiros P, Kolenik S, Heald P, Braverman I, Edelson R, Kacinski B. Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma. Journal Of The American Academy Of Dermatology 1996, 35: 69-73. PMID: 8682967, DOI: 10.1016/s0190-9622(96)90499-5.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapyCutaneous T-cell lymphomaRecurrent cutaneous T-cell lymphomaComplete responseT-cell lymphomaElectron beam therapySecond courseMedian disease-free intervalThird courseAdditional coursesBeam therapyDisease-free intervalTreatment of patientsAcceptable risk profileForm of therapyMedian doseMedian survivalMild erythemaPatientsInitial courseTherapyVariety of modalitiesRisk profileEntire groupLocalized radiation
1995
Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation.
Licata AG, Wilson LD, Braverman IM, Feldman AM, Kacinski BM. Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation. JAMA Dermatology 1995, 131: 432-5. PMID: 7726585, DOI: 10.1001/archderm.131.4.432.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapyCutaneous T-cell lymphomaT-cell lymphomaSquamous cell carcinomaBasal cell carcinomaElectron beam therapyAdditional radiation therapyCell carcinomaCutaneous malignanciesOral psoralenAdditional therapyMalignant melanomaRadiation therapyBeam therapyTotal skin electron beam radiationFurther radiation therapyGroup of patientsNonmelanoma skin cancerAnecdotal case reportsPrevious large studiesTopical mechlorethamineHydrochloride therapyCase reportPatientsCarcinoma
1994
Impact of non-CTCL dermatologic diagnoses and adjuvant therapies on cutaneous T-cell lymphoma patients treated with total skin electron beam radiation therapy
Wilson L, Cooper D, Goodrich A, Friedman N, Feldman A, Braverman I, Kacinski B. Impact of non-CTCL dermatologic diagnoses and adjuvant therapies on cutaneous T-cell lymphoma patients treated with total skin electron beam radiation therapy. International Journal Of Radiation Oncology • Biology • Physics 1994, 28: 829-837. PMID: 8138435, DOI: 10.1016/0360-3016(94)90102-3.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overChemotherapy, AdjuvantHumansLymphoma, T-Cell, CutaneousMiddle AgedPUVA TherapySkinSurvival RateConceptsTotal skin electron beam therapySystemic adjuvant therapyRelapse-free survivalDoxorubicin/cyclophosphamide chemotherapyShorter relapse-free survivalElectron beam therapyAdjuvant therapyDermatologic diagnosesBeam therapyCyclophosphamide chemotherapyFollicular mucinosisOverall survivalT2 patientsExtracorporeal photopheresisLymphomatoid papulosisCutaneous relapseTotal skin electron beam radiation therapyCutaneous T-cell lymphoma patientsT-cell lymphoma patientsBetter relapse-free survivalClinical complete responseCohort of patientsElectron beam radiation therapyBeam radiation therapyAdjuvant chemotherapy
1993
Transformation in Cutaneous T-Cell Lymphoma
Braverman I, Redfern C. Transformation in Cutaneous T-Cell Lymphoma. Journal Of Investigative Dermatology 1993, 101: 249-251. PMID: 8370959, DOI: 10.1111/1523-1747.ep12365124.Peer-Reviewed Original ResearchCell Transformation, NeoplasticHumansLymphoma, T-Cell, CutaneousMaleMiddle AgedMycosis FungoidesSezary SyndromeCyclosporine treatment of refractory T‐cell lymphomas
Cooper D, Braverman I, Sarris A, Durivage H, Saidman B, Davis C, Hait W. Cyclosporine treatment of refractory T‐cell lymphomas. Cancer 1993, 71: 2335-2341. PMID: 8453556, DOI: 10.1002/1097-0142(19930401)71:7<2335::aid-cncr2820710727>3.0.co;2-d.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCyclosporineFemaleHumansLymphoma, T-Cell, CutaneousLymphoma, T-Cell, PeripheralMaleMiddle AgedConceptsCutaneous T-cell lymphomaPeripheral T-cell lymphomaRefractory T-cell lymphomaT-cell lymphomaMost patientsDisease progressionReinstitution of therapySubsequent graft rejectionPhase II trialT cell expansionT-cell neoplasmsTranscription of cytokinesCyclosporine treatmentClinical remissionII trialPrevious therapyRecurrent diseaseCsA administrationGraft rejectionRenal toxicityAntiinflammatory effectsRapid recurrenceTransplanted organsInterleukin-2Radiation therapy
1991
The Use of Immunohistologic Analysis in Differentiating Cutaneous T-cell Lymphoma From Psoriasis and Dermatitis
Verga M, Braverman I. The Use of Immunohistologic Analysis in Differentiating Cutaneous T-cell Lymphoma From Psoriasis and Dermatitis. JAMA Dermatology 1991, 127: 1503-1510. PMID: 1929457, DOI: 10.1001/archderm.1991.01680090067006.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaCTCL lesionsImmunohistologic analysisEarly-stage cutaneous T-cell lymphomaBenign inflammatory diseaseImmunohistologic patternsDR antibodiesHLA-DRBiopsy specimensInflammatory diseasesPsoriatic lesionsImmunoperoxidase techniquePsoriatic skinDermatitic lesionsExtensive stainingPsoriasisNormal skinDermatitisLesionsPatientsMonoclonal antibodiesEpidermal areaLymphomaAntibodies